



60504_Auto_Edited.docx

Quotes Excluded
Bibliography Excluded8%
SIMILAR**5** Name of Journal: *World Journal of Methodology*

Manuscript NO: 60504

Manuscript Type: SYSTEMATIC REVIEWS

Tocilizumab as **treatment** for COVID-19: A systematic review and meta-analysisPetrelli F *et al.* Tocilizumab for COVID-19 infectionFausto Petrelli, Sara Cherri, Michele Ghidini, Gianluca Perego, Antonio Ghidini,
Alberto Zaniboni

Match Overview

1	Internet 65 words crawled on 09-Jul-2020 www.researchsquare.com	1%
2	Crossref 58 words Muhammad Aziz, Hossein Haghbin, Emad Abu Sitta, Yusuf Nawras et al. "Efficacy of Tocilizumab in COVID-19: A Sy ...	1%
3	Crossref 52 words E. Nasonov, M. Samsonov. "The role of Interleukin 6 inhil ... ors in therapy of severe COVID-19", Biomedicine & Pharm	1%
4	Internet 47 words crawled on 25-Aug-2020 www.frontiersin.org	1%
5	Internet 39 words crawled on 09-Jul-2019 f6publishing.blob.core.windows.net	1%
6	Crossref 24 words Ming Zhao. "Cytokine storm and immunomodulatory therap	<1%

Tocilizumab as treatment for COVID-19: A systematic review and me



ALL

IMAGES

VIDEOS

6,420,000 Results

Any time ▼

Tocilizumab for severe COVID-19: a systematic review and ...

<https://pubmed.ncbi.nlm.nih.gov/32712333>

This **systemic review** and meta-analysis aimed to assess the efficacy of **tocilizumab** for the **treatment** of **severe coronavirus disease 2019 (COVID-19)**. Candidate studies up to 24 May 2020 were identified from PubMed, Cochrane Library, Embase, medRxiv and bioRxiv. **Treatment** outcomes included mortality, r ...

Cited by: 11

Author: Shao Huan Lan, Chih Cheng Lai, Hui Ting...

Publish Year: 2020

Tocilizumab for severe COVID-19: a systematic review and ...

<https://www.sciencedirect.com/science/article/pii/S0924857920302867>

Sep 01, 2020 · **Systemic review** and meta-analysis assessing the efficacy of **tocilizumab** for **treatment** of **severe COVID-19**. • All-cause mortality was similar between **tocilizumab** and control groups (16.3% vs. 24.1%; RR = 0.62). • Risk of ICU admission was similar between **tocilizumab** and control groups (35.0% vs. 15.8%; RR = 1.51). •

Cited by: 11

Author: Shao Huan Lan, Chih Cheng Lai, Hui Ting...

Publish Year: 2020

Use of Tocilizumab in COVID-19: A Systematic Review and ...

<https://pubmed.ncbi.nlm.nih.gov/33178522>

Background and objectives A flare-up in coronavirus disease 2019 (COVID-19) cases threatens the health of people, and though there is no proven pharmacological **treatment**, many analytical studies have suggested that interleukin-6 (IL-6) levels are elevated in cases of severe COVID-19 and that the ant ...

Use of Tocilizumab in COVID-19: A Systematic Review and ...

<https://www.docwirenews.com/abstracts/use-of...> ▼

Nov 12, 2020 · This is a critical **review** of studies aiming to assess the safety and efficacy of **tocilizumab** as compared to the standard regimen in patients with COVID-19. Materials and methods Online databases (PubMed and Cochrane) were searched until June 29, 2020, for original articles investigating the immunological response in COVID-19 and its **treatment** ...

Use of Tocilizumab in COVID-19: A Systematic Review and ...

<https://www.cureus.com/articles/42647-use-of...> ▼

Tocilizumab as treatment for COVID-19: A systematic review and me



ALL

IMAGES

VIDEOS

6,600,000 Results

Any time ▾

Tocilizumab for severe COVID-19: a systematic review and ...

<https://pubmed.ncbi.nlm.nih.gov/32712333>

This **systemic review and meta-analysis** aimed to assess the efficacy of **tocilizumab** for the **treatment of severe coronavirus disease 2019 (COVID-19)**. Candidate studies up to 24 May 2020 were identified from PubMed, Cochrane Library, Embase, medRxiv and bioRxiv. Treatment outcomes included mortality, r ...

Cited by: 31**Author:** Shao Huan Lan, Chih Cheng Lai, Hui Ti...**Publish Year:** 2020

Use of Tocilizumab in COVID-19: A Systematic Review and ...

<https://www.cureus.com/articles/42647-use-of...> ▾

A flare-up in **coronavirus disease 2019 (COVID-19)** cases threatens the health of people, and though there is no proven pharmacological treatment, many analytical studies have suggested that interleukin-6 (IL-6) levels are elevated in cases of severe COVID-19 and that the anti-IL-6 biologic agent tocilizumab may be beneficial.

Cited by: 3**Author:** Sohny Kotak, Mahima Khatri, Mehreen ...**Publish Year:** 2020

Efficacy of tocilizumab in COVID-19: A systematic review ...

<https://pubmed.ncbi.nlm.nih.gov/32918755>

The efficacy of tocilizumab (TOC), monoclonal antibody against interleukin-6 (IL-6) receptor, in patients with coronavirus disease-2019 (COVID-19) patients has led to conflicting results. We performed a systematic review and meta-analysis to compare the efficacy of addition of **TOC to standard of care (SOC)** versus SOC in patients with COVID-19.

Cited by: 13**Author:** Muhammad Aziz, Hossein Haghbin, Ema...**Publish Year:** 2021

ALL

IMAGES

VIDEOS

6,810,000 Results

Any time ▾

[Tocilizumab for severe COVID-19: a systematic review and ...](#)

<https://pubmed.ncbi.nlm.nih.gov/32712333>

This **systemic review and meta-analysis** aimed to assess the efficacy of **tocilizumab** for the **treatment of severe coronavirus disease 2019 (COVID-19)**. Candidate studies up to 24 May 2020 were identified fro...

Cited by: 52

Author: Shao Huan Lan, Chih Cheng Lai, Hui Ting H...

Publish Year: 2020

[Tocilizumab for severe COVID-19: a systematic review and ...](#)

<https://reference.medscape.com/medline/abstract/32712333> ▾

This **systemic review and meta-analysis** aimed to assess the efficacy of **tocilizumab** for the **treatment of severe coronavirus disease 2019 (COVID-19)**. Candidate studies up to 24 May 2020 were...

[Mortality in tocilizumab-treated patients with COVID-19: a ...](#)

<https://pubmed.ncbi.nlm.nih.gov/33275094>

This study showed that the mortality pooled prevalence in **TCZ-treated patients** is lower than the overall **mortality** reported in patients with severe COVID-19. **Mortality in tocilizumab-treated patients** with...

Cited by: 3

Author: Onorina Berardicurti, Piero Ruscitti, France...

Publish Year: 2020

[Use of Tocilizumab in COVID-19: A Systematic Review and ...](#)

<https://www.cureus.com/articles/42647-use-of...> ▾

A flare-up in **coronavirus disease 2019 (COVID-19)** cases threatens the health of people, and though there is no proven pharmacological treatment, many analytical studies have suggested that interleukin-6 (IL-6)...

Cited by: 2

Author: Sohny Kotak, Mahima Khatri, Mehreen Mali...

Publish Year: 2020

[Efficacy and safety of tocilizumab in COVID-19 patients: a ...](#)

<https://pubmed.ncbi.nlm.nih.gov/33161150>

Conclusions: Cumulative moderate-certainty evidence shows that **tocilizumab** reduces the risk of mechanical ventilation in hospitalized **COVID-19** patients. While RCTs showed that tocilizumab did not...

Cited by: 17

Author: Imad M. Tleyjeh, Zakariya Kashour, Mouss...

Publish Year: 2021

[Efficacy of tocilizumab in COVID-19: A systematic review ...](#)

<https://pubmed.ncbi.nlm.nih.gov/32918755>

The efficacy of tocilizumab (TOC), monoclonal antibody against interleukin-6 (IL-6) receptor, in patients with severe COVID-19 (COVID-19) is still unclear. This systematic review and meta-analysis...

Search Tools

Turn off Hover Translation (关闭取词)